Engineering a new β-cell: A critical venture requiring special attention to constantly changing physiological needs

Seminars in Cell and Developmental Biology

Volumn 15, Issue 3, 2004, Pages 359-370

  Kahn, Steven E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Amyloid; Insulin resistance; Insulin secretion; Type 1 diabetes; Type 2 diabetes

Indexed keywords

AMYLOID; PEPTIDE;

BODY WEIGHT; CARDIOVASCULAR DISEASE; CELL SECRETION; DIABETIC OBESITY; DISEASE SEVERITY; EXERCISE; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INNER CELL MASS; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PUBERTY; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SUBSTITUTION THERAPY; SURVIVAL RATE;

EID: 2342614852     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2004.02.005     Document Type: Article

References (100)

1. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diab Care 1997;20:1183-97.
2. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diab. Med. 15:1998;539-553
3. Rewers M. The changing face of the epidemiology of insulin-dependent diabetes mellitus (IDDM): research designs and models of disease causation. Ann. Med. 23:1991;419-426
4. Libman I., Songer T., LaPorte R. How many people in the U.S. have IDDM? Diab. Care. 16:1993;841-842
5. Zimmet P., Shaw J., Alberti K.G. Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diab. Med. 20:2003;693-702
6. Jensen C.C., Cnop M., Hull R.L., Fujimoto W.Y., Kahn S.E. American Diabetes Association GENNID Study Group. β-Cell function is the major determinant of oral glucose tolerance in four ethnic groups in the United States. Diabetes. 51:2002;2170-2178
7. Naik RG, Lernmark A, Palmer JP. The pathophysiology and genetics of type 1 (insulin-dependent) diabetes mellitus. In: Porte Jr D, Sherwin RS, Baron A, editors. Diabetes mellitus. New York, NY: McGraw-Hill; 2003. p. 301-29.
8. Kahn SE, Porte Jr D. The pathophysiology and genetics of type 2 diabetes mellitus. In: Porte Jr D, Sherwin RS, Baron A, editors. Diabetes mellitus, New York, NY: McGraw-Hill; 2003. p. 331-65.
9. Karjalainen J., Salmela P., Ilonen J., Surcel H.M., Knip M. A comparison of childhood and adult type I diabetes mellitus. N. Engl. J. Med. 320:1989;881-886
10. Eisenbarth G.S. Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 314:1986;1360-1368
11. Kahn S.E. The importance of beta-cell failure in the development and progression of type 2 diabetes. J. Clin. Endocrinol. Metab. 86:2001;4047-4058
12. Mitrakou A., Kelley D., Mokan M., Veneman T., Pangburn T., Reilly J., et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N. Engl. J. Med. 326:1992;22-29
13. Ward W.K., LaCava E.C., Paquette T.L., Beard J.C., Wallum B.J., Porte D. Jr. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and experimental insulin resistance. Diabetologia. 30:1987;698-702
14. Kahn S.E., Halban P.A. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes. 46:1997;1725-1732
15. Glauber H.S., Henry R.R., Wallace P., Frank B.H., Galloway J.A., Cohen R.M., et al. The effects of biosynthetic human proinsulin on carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 316:1987;443-449
16. Kloppel G., Lohr M., Habich K., Oberholzer M., Heitz P.U. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv. Synth. Pathol. Res. 4:1985;110-125
17. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 52:2003;102-110
18. Westermark P. Quantitative studies of amyloid in the islets of Langerhans. Ups J. Med. Sci. 77:1972;91-94
19. Clark A., Saad M.F., Nezzer T., Uren C., Knowler W.C., Bennett P.H., et al. Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia. 33:1990;285-289
20. Kahn S.E., Andrikopoulos S., Verchere C.B. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes. 48:1999;241-253
21. Kahn S.E., Prigeon R.L., McCulloch D.K., Boyko E.J., Bergman R.N., Schwartz M.W., et al. Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 42:1993;1663-1672
22. Kruszynska Y.T., Home P.D., Hanning I., Alberti K.G. Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia. 30:1987;16-21
23. Polonsky K.S., Given B.D., Van Cauter E. Twenty-four-hour profiles and patterns of insulin secretion in normal and obese subjects. J. Clin. Invest. 81:1988;442-448
24. Ward W.K., Beard J.C., Halter J.B., Pfeifer M.A., Porte D. Jr. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diab. Care. 7:1984;491-502
25. Creutzfeldt W. The incretin concept today. Diabetologia. 16:1979;75-85
26. Nauck M.A. Is glucagon-like peptide 1 an incretin hormone? Diabetologia. 42:1999;373-379
27. Arslanian S., Suprasongsin C. Insulin sensitivity, lipids, and body composition in childhood: is "syndrome X" present? J. Clin. Endocrinol. Metab. 81:1996;1058-1062
28. Goran M.I., Gower B.A. Longitudinal study on pubertal insulin resistance. Diabetes. 50:2001;2444-2450
29. Smith C.P., Dunger D.B., Williams A.J., Taylor A.M., Perry L.A., Gale E.A., et al. Relationship between insulin insulin-like growth factor I, and dehydroepiandrosterone sulfate concentrations during childhood, puberty, and adult life. J. Clin. Endocrinol. Metab. 68:1989;932-937
30. Caprio S., Plewe G., Diamond M.P., Simonson D.C., Boulware S.D., Sherwin R.S., et al. Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J. Pediatr. 114:1989;963-967
31. Arslanian S. Insulin secretion and sensitivity in healthy African-American vs. American white children. Clin. Pediatr. (Phila.). 37:1998;81-88
32. Goran M.I., Bergman R.N., Cruz M.L., Watanabe R. Insulin resistance and associated compensatory responses in African-American and Hispanic children. Diab. Care. 25:2002;2184-2190
33. Buchanan T.A., Metzger B.E., Freinkel N., Bergman R.N. Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am. J. Obstet. Gynecol. 162:1990;1008-1014
34. Sivan E., Chen X., Homko C.J., Reece E.A., Boden G. Longitudinal study of carbohydrate metabolism in healthy obese pregnant women. Diab. Care. 20:1997;1470-1475
35. Sorenson R.L., Brelje T.C. Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm. Metab. Res. 29:1997;301-307
36. Kahn S.E., Larson V.G., Beard J.C., Cain K.C., Fellingham G.W., Schwartz R.S., et al. Effect of exercise on insulin action, glucose tolerance and insulin secretion in aging. Am. J. Physiol. 258:1990;E937-E943
37. Chen M., Bergman R.N., Porte D. Jr. Insulin resistance and β-cell dysfunction in aging: the importance of dietary carbohydrate. J. Clin. Endocrinol. Metab. 67:1988;951-957
38. Schwartz R.S., Shuman W.P., Bradbury V.L., Cain K.C., Fellingham G.W., Beard J.C., et al. Body fat distribution in healthy young and older men. J. Gerontol. 45:1990;M181-M185
39. Cefalu W.T., Wang Z.Q., Werbel S., Bell-Farrow A., Crouse J.R. III, Hinson W.H., et al. Contribution of visceral fat mass to the insulin resistance of aging. Metabolism. 44:1995;954-959
40. Chen M., Bergman R.N., Pacini G., Porte D. Jr. Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased β-cell function. J. Clin. Endocrinol. Metab. 60:1985;13-20
41. Kahn S.E., Larson V.G., Schwartz R.S., Beard J.C., Cain K.C., Fellingham G.W., et al. Exercise training delineates the importance of B-cell dysfunction to the glucose intolerance of human aging. J. Clin. Endocrinol. Metab. 74:1992;1336-1342
42. LeBlanc J., Nadeau A., Richard D., Tremblay A. Studies on the sparing effect of exercise on insulin requirements in human subjects. Metabolism. 30:1981;1119-1124
43. Heath G.W., Gavin J.R. III, Hinderliter J.M., Hagberg J.M., Bloomfield S.A., Holloszy J.O. Effects of exercise and lack of exercise on glucose tolerance and insulin sensitivity. J. Appl. Physiol. 55:1983;512-517
44. Prigeon R.L., Kahn S.E., Porte D. Jr. Changes in insulin sensitivity glucose effectiveness and B-cell function in regularly exercising subjects. Metabolism. 44:1995;1259-1263
45. Seals D.R., Hagberg J.M., Hurley B.F., Ehsani A.A., Holloszy J.O. Effects of endurance training on glucose tolerance and plasma lipid levels in older men and women. JAMA. 252:1984;645-649
46. Schwartz R.S., Shuman W.P., Larson V., Cain K.C., Fellingham G.W., Beard J.C., et al. The effect of intensive endurance exercise training on body fat distribution in young and older men. Metabolism. 40:1991;545-551
47. Colman E., Katzel L.I., Rogus E., Coon P., Muller D., Goldberg A.P. Weight loss reduces abdominal fat and improves insulin action in middle-aged and older men with impaired glucose tolerance. Metabolism. 44:1995;1502-1508
48. Goodpaster B.H., Kelley D.E., Wing R.R., Meier A., Thaete F.L. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes. 48:1999;839-847
49. Cnop M., Landchild M.J., Vidal J., Havel P.J., Knowles N.G., Carr D.R., et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes. 51:2002;1005-1015
50. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
51. Robertson R.P., Lanz K.J., Sutherland D.E., Seaquist E.R. Relationship between diabetes and obesity 9 to 18 years after hemipancreatectomy and transplantation in donors and recipients. Transplantation. 73:2002;736-741
52. Marangou A.G., Alford F.P., Ward G., Liskaser F., Aitken P.M., Weber K.M., et al. Hormonal effects of norepinephrine on acute glucose disposal in humans: a minimal model analysis. Metabolism. 37:1988;885-891
53. Deibert D.C., DeFronzo R.A. Epinephrine-induced insulin resistance in man. J. Clin. Invest. 63:1980;939-946
54. van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., et al. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345:2001;1359-1367
55. Kahn S.E., D'Alessio D.A., Schwartz M.W., Fujimoto W.Y., Ensinck J.W., Taborsky G.J. Jr., et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes. 39:1990;634-638
56. Westermark P., Wernstedt C., Wilander E., Hayden D.W., O'Brien T.D., Johnson K.H. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islets. Proc. Natl. Acad. Sci. U.S.A. 84:1987;3881-3885
57. Cooper G.J.S., Willis A.C., Clark A., Turner R.C., Sim R.B., Reid K.B.M. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. U.S.A. 84:1987;8628-8632
58. Malaisse W.J., Sener A., Herchuelz A., Hutton J.C. Insulin release: the fuel hypothesis. Metabolism. 28:1979;373-386
59. Matschinsky F.M., Glaser B., Magnuson M.A. Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes. 47:1998;307-315
60. Malaisse W.J., Rasschaert J., Conget I., Sener A. Hexose metabolism in pancreatic islets. Regulation of aerobic glycolysis and pyruvate decarboxylation. Int. J. Biochem. 23:1991;955-959
61. Aguilar-Bryan L., Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr. Rev. 20:1999;101-135
62. German M.S., Wang J. The insulin gene contains multiple transcriptional elements that respond to glucose. Mol. Cell Biol. 14:1994;4067-4075
63. Ahlgren U., Jonsson J., Jonsson L., Simu K., Edlund H. Beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev. 12:1998;1763-1768
64. Davidson H.W., Rhodes C.J., Hutton J.C. Intraorganellar calcium and pH control proinsulin cleavage in the pancreatic β-cell via two distinct site-specific endopeptidases. Nature. 333:1988;93-96
65. Smeekens S.P., Steiner D.F. Identification of a human insulinoma cDNA encoding a novel mammalian protein structurally related to the yeast dibasic processing protease Kex2. J. Biol. Chem. 265:1990;2997-3000
66. Smeekens S.P., Avruch A.S., LaMendola J., Chan S.J., Steiner D.F. Identification of a cDNA encoding a second putative prohormone convertase related to PC2 in AtT20 cells and islets of Langerhans. Proc. Natl. Acad. Sci. U.S.A. 88:1991;340-344
67. Nagamatsu S., Nishi M., Steiner D.F. Biosynthesis of islet amyloid polypeptide. Elevated expression in mouse beta TC3 cells. J. Biol. Chem. 266:1991;13737-13741
68. 2+ and G-proteins. Diab. Rev. 4:1996;276-297
69. Drucker D.J. Minireview: the glucagon-like peptides. Endocrinology. 142:2001;521-527
70. Skelly R.H., Bollheimer L.C., Wicksteed B.L., Corkey B.E., Rhodes C.J. A distinct difference in the metabolic stimulus-response coupling pathways for regulating proinsulin biosynthesis and insulin secretion that lies at the level of a requirement for fatty acyl moieties. Biochem. J. 331:1998;553-561
71. Welsh M., Scherberg N., Gilmore R., Steiner D.F. Translational control of insulin biosynthesis: evidence for regulation of elongation, initiation and signal-recognition-particle-mediated translational arrest by glucose. Biochem. J. 235:1986;459-467
72. Faradji R.N., Havari E., Chen Q., Gray J., Tornheim K., Corkey B.E., et al. Glucose-induced toxicity in insulin-producing pituitary cells that coexpress GLUT2 and glucokinase. Implications for metabolic engineering. J. Biol. Chem. 276:2001;36695-36702
73. Ishihara H., Wang H., Drewes L.R., Wollheim C.B. Overexpression of monocarboxylate transporter and lactate dehydrogenase alters insulin secretory responses to pyruvate and lactate in beta cells. J. Clin. Invest. 104:1999;1621-1629
74. Farfari S., Schulz V., Corkey B., Prentki M. Glucose-regulated anaplerosis and cataplerosis in pancreatic beta-cells: possible implication of a pyruvate/citrate shuttle in insulin secretion. Diabetes. 49:2000;718-726
75. Nestorowicz A., Inagaki N., Gonoi T., Schoor K.P., Wilson B.A., Glaser B., et al. A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism. Diabetes. 46:1997;1743-1748
76. Henquin J.C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. 49:2000;1751-1760
77. Deeney J.T., Gromada J., Hoy M., Olsen H.L., Rhodes C.J., Prentki M., et al. Acute stimulation with long chain acyl-CoA enhances exocytosis in insulin-secreting cells (HIT T-15 and NMRI beta-cells). J. Biol. Chem. 275:2000;9363-9368
78. Dillon J.S., Tanizawa Y., Wheeler M.B., Leng X.H., Ligon B.B., Rabin D.U., et al. Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology. 133:1993;1907-1910
79. Otonkoski T., Hayek A. Constitution of a biphasic insulin response to glucose in human fetal pancreatic beta-cells with glucagon-like peptide 1. J. Clin. Endocrinol. Metab. 80:1995;3779-3783
80. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91.
81. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346:2002;1692-1698
82. Elbein S.C. Perspective: the search for genes for type 2 diabetes in the post-genome era. Endocrinology. 143:2002;2012-2018
83. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 287:2002;360-372
84. DeWitt D.E., Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 289:2003;2254-2264
85. Beard J.C., Halter J.B., Best J.D., Pfeifer M.A., Porte D. Jr. Dexamethasone-induced insulin resistance enhances B-cell responsiveness to glucose level in normal men. Am. J. Physiol. 247:1984;E592-E596
86. Kalhan S.C., Adam P.A.J. Inhibitory effect of prednisone on insulin secretion in man: model for duplication of blood glucose concentration. J. Clin. Endocrinol. Metab. 41:1975;600-610
87. Matsumoto K., Yamasaki H., Akazawa S., Sakamaki H., Ishibashi M., Abiru N., et al. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic β-cells in normal men. J. Clin. Endocrinol. Metab. 81:1996;2621-2626
88. Kahn S.E., Horber F.F., Prigeon R.L., Haymond M.W., Porte D. Jr. Effect of glucocorticoid and growth hormone treatment on proinsulin levels in humans. Diabetes. 42:1993;1082-1085
89. Wahlstrom H.E., Lavelle-Jones M., Endres D., Akimoto R., Kolterman O., Moossa A.R. Inhibition of insulin release by cyclosporine and production of peripheral insulin resistance in the dog. Transplantation. 49:1990;600-604
90. Dmitrewski J., Krentz A.J., Mayer A.D., Buckels J.A., Barnes A.D., Smith J., et al. Metabolic and hormonal effects of tacrolimus (FK506) or cyclosporin immunosuppression following renal transplantation. Diab. Obes. Metab. 3:2001;287-292
91. Boots J.M., van Duijnhoven E.M., Christiaans M.H., Wolffenbuttel B.H., van Hooff J.P. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J. Am. Soc. Nephrol. 13:2002;221-227
92. Gruessner R.W., Sutherland D.E., Drangstveit M.B., Troppmann C., Gruessner A.C. Use of FK 506 in pancreas transplantation. Transpl. Int. 9:1996;S251-S257
93. Gruessner R.W. Tacrolimus Pancreas Transplant Study Group. Tacrolimus in pancreas transplantation: a multicenter analysis. Clin. Transpl. 11:1997;299-312
94. Purnell J.Q., Hokanson J.E., Marcovina S.M., Steffes M.W., Cleary P.A., Brunzell J.D. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA. 280:1998;140-146
95. Gu K., Cowie C.C., Harris M.I. Diabetes and decline in heart disease mortality in US adults. JAMA. 281:1999;1291-1297
96. Marangou A.G., Weber K.M., Boston R.C., Aitken P.M., Heggie J.C., Kirsner R.L.G., et al. Metabolic consequences of prolonged hyperinsulinemia in humans: evidence for induction of insulin insensitivity. Diabetes. 35:1986;1383-1389
97. Ward G.M., Walters J.M., Aitken P.M., Best J.D., Alford F.P. Effects of prolonged pulsatile hyperinsulinemia in humans. Enhancement of insulin sensitivity. Diabetes. 39:1990;501-507
98. Schneider D.J., Nordt T.K., Sobel B.E. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells. Diabetes. 41:1992;890-895
99. Pfeifer M.A., Halter J.B., Porte D. Jr. Insulin secretion in diabetes mellitus. Am. J. Med. 70:1981;579-588
100. Utzschneider K.M., Carr D.B., Barsness S.L., Kahn S.E., Schwartz R.S. Weight loss is associated with an improvement in β-cell function in older subjects. Diabetes. 52(Suppl. 1):2003;A28